Other Events ·
Clearmind Medicine Inc. reported positive ex vivo mucoadhesion results for its intranasal formulation of MEAI…
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. reported positive ex vivo mucoadhesion results for its intranasal formulation of MEAI (5-Methoxy-2-aminoindane), demonstrating improved nasal residence time compared to a standard solution. The mucoadhesive polymer system in the new formulation aims to maximize MEAI absorption and therapeutic potential for treating Alcohol Use Disorder. Clearmind Medicine Inc. is a clinical-stage biotechnology company developing non-hallucinogenic neuroplastogen-derived treatments for addiction and weight management.